Key facts
- Inocras’s last known valuation is $323.0M (Nov 2023).
- It has raised $51.7M; the latest was Later Stage VC in Jun 2025.
- Notable investors include Samsung Venture Investment, InterVest, Schmidt (South Korea), Ministry of SMEs and Startups, VNTG — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Inocras
- ·The full record, as it builds
Funding rounds
No funding rounds for Inocras are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Inocras
Developer of a genome-based big data platform designed to pave the way for a new era of personalized precision medicine. The company's platform offers insights through the precise interpretation of full-length genome big data, enabling clients to employ the information effectively in their operations.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2020
- Employees
- 40
- Website
- inocras.com/
- Ownership
- Privately Held (backing)
Inocras doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Inocras shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Inocras in its N-PORT filings yet. We sweep new filings monthly.